Ipratropium Teva (Ipratropium Bromide Monohydrate)

Ipratropium bromide works by competitively blocking muscarinic acetylcholine receptors (M1, M2, M3) in the airway smooth muscle and submucosal glands. This inhibition prevents vagally mediated bronchoconstriction, leading to airway dilation and decreased mucus secretion, which helps relieve breathing difficulties.

The appropriate dose of Ipratropium Teva is determined by the prescribing healthcare professional based on the patient’s condition, severity, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed by the prescriber.

The safety of ipratropium bromide in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To order Ipratropium Teva, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details, and any necessary import documentation.

Ipratropium Teva belongs to the anticholinergic class of bronchodilators, which act by blocking muscarinic receptors, unlike beta‑agonists that stimulate β2 receptors. It is often used in combination with β2‑agonists for additive bronchodilation, offering an alternative mechanism of action and a favorable safety profile for patients who may not tolerate β‑agonists well.

Ipratropium Teva should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use to maintain stability.

Ipratropium Teva is administered by inhalation using a nebulizer or metered‑dose inhaler, as directed by the prescriber. The patient inhales the medication directly into the lungs, allowing rapid onset of bronchodilation. Proper inhalation technique should be taught by a healthcare professional.

Serious risks include paradoxical bronchospasm, angioedema, severe allergic reactions, tachycardia, urinary retention, and acute glaucoma. Patients should be instructed to seek immediate medical attention if they experience worsening breathing difficulty, swelling of the face or throat, rapid heartbeat, or visual disturbances.

Ipratropium Teva should not be used by individuals with known hypersensitivity to ipratropium bromide or any component of the formulation. Caution is also advised for patients with narrow‑angle glaucoma, urinary retention, or severe cardiovascular disease, and it should be avoided in those with contraindicated conditions as determined by their physician.